Synonyms: LY 2811376 | LY-2811376
Compound class:
Synthetic organic
Comment: LY2811376 is a non-peptidic BACE1 inhibitor for Alzheimer's Disease. Aβ reductions in lumbar CSF were measured after oral dosing in humans but development was halted because of toxicology findings but these may not be related to BACE1 inhibition.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
LY2811376, a BACE1 inhibitor for Alzheimer's Disease showed robust and sustained reduction of lumbar CSF Aβ in healthy volunteers accompanied by sustained reduction of lumbar CSF sAPPβ, the primary cleavage product of BACE1 cleavage of APP. The retinal pathology in longer-term nonclinical toxicology studies that caused development to be stopped appears to be off-target because a similar adverse effect was obtained with long-term dosing of BACE1 KO mice with LY2811376. [1] |